FDA Clears Lilly’s Foundayo Pill

WASHINGTON — Federal health regulators approved Eli Lilly’s oral obesity medicine Foundayo (orforglipron), creating a new daily pill option in the fast-growing GLP-1 market, according to U.S. Food and Drug Administration, Eli Lilly and Company, The Associated Press, Reuters, The Guardian, and PBS NewsHour. Each of the bullet points immediately below have been confirmed by at least four of the six respected sources we curated on this story.

• The FDA approved Foundayo (orforglipron) for chronic weight management in adults with obesity, and in adults with overweight who have at least one weight-related medical condition.
• Foundayo is a once-daily oral GLP-1 treatment and can be taken without food or water timing restrictions.
• The approval moved through the FDA’s voucher-based accelerated pathway, with the agency saying the review was completed in 50 days.
• Lilly said U.S. prescriptions are being accepted immediately through LillyDirect, with shipping set to begin April 6 before broader pharmacy and telehealth rollout.
• Late-stage trial results cited across major coverage showed clinically meaningful, double-digit average weight reduction over 72 weeks at higher doses versus placebo.

Additional Details Reported

Pricing and market rollout

Company guidance and follow-up reporting said eligible commercially insured patients may pay as little as $25 per month with savings support, while self-pay prices begin at $149 monthly and rise with higher doses.

Coverage also positioned the launch as a direct challenge to Novo Nordisk’s oral Wegovy product, with both companies now competing in oral and injectable GLP-1 segments.

Label warnings and tolerability

Regulatory documents and company safety disclosures include a boxed warning for thyroid C-cell tumor risk and caution against use in patients with specific endocrine cancer histories.

The most frequently reported side effects were gastrointestinal, including nausea, vomiting, constipation, and diarrhea; these effects were generally described as consistent with the GLP-1 drug class.

How we report: We select the day’s most important stories, confirm facts across multiple reputable sources, and avoid anonymous sourcing. Our goal is clear, balanced coverage you can trust—because transparency and verification matter for informed readers.